Data from preclinical studies to date demonstrate encouraging antitumor activity of seribantumab in cancer cell lines and patient-derived xenograft models of various tumor types, including lung, ovarian, and pancreatic tumors harboring different NRG1 fusions and, therefore, support clinical investigations of seribantumab in patients with these types of tumors [9]. This evidence concerns the gene NRG1 and neoplasm.